Navigation Links
Hiemstra Approved to Manufacture Medical Devices in New CER
Date:1/9/2008

Meeting medical clients' needs from product design and development through

manufacturing

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Hiemstra Product Development, a leading product design and development company, announced today that it has received Food and Drug Branch (FDB) approval from the California Department of Health Services' Division of Food, Drug and Radiation Safety to manufacture class I - III medical devices in its 750 sq. ft., class 10,000 CER (clean room). Hiemstra can now help customers bring their medical technologies from concept to clinical release faster than before by offering world class product design and development, as well as manufacturing services, all under one roof.

This FDB approval enables Hiemstra to be a valuable manufacturing resource for customers through first-in-man, ongoing clinical trials, and low-to-mid volume production needs during early ramp-up or as ongoing manufacturing support. A few examples of the types of devices that Hiemstra's state-of-the-art CER can support are implants, surgical tools, catheters and catheter-based delivery systems.

"Now, Hiemstra is better equipped to increase speed-to-market by offering not only leading product design and development, but also manufacturing, in a one-stop-shop facility," noted Patrick Owens, Director of Operations at Hiemstra. "Our CER provides the flexibility to manufacture a few hundred to 30,000 units depending on the medical technology."

The engineering team at Hiemstra maintains in-depth knowledge of manufacturing processes to provide clients with additional support to ensure appropriate production resources are selected and to ensure a smooth transition to a high-volume production facility, as needed.

About Hiemstra:

Hiemstra Product Development is a leading medical product design and development company. Founded in 1991, this San Francisco-based firm is built on its unparalleled integration of indus
'/>"/>

SOURCE Hiemstra Product Development
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
2. Pennsylvania American Waters Rate Case Approved
3. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
4. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
5. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
6. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
7. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
8. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
9. FDA Cracks Down on Unapproved Cough Medicines
10. $52.5 Million Settlement Against Sepracor Inc. Approved
11. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... Oregon (PRWEB) February 28, 2015 The ... Oregon, is offering a new special. Throughout all ... relines. , This service can ... sleep problems and pain. Patients may notice certain symptoms ... need relining. These symptoms include: , 1.    Pain, clicking, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... to discuss federal testosterone lawsuits that have been filed ... scheduled for the second week in March, the Firm ... the Court’s website, parties involved in the federal litigation ... to address matters related to prescription therapy treatments designed ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... the disease, , , WEDNESDAY, April 15 (HealthDay News) ... the tracking of changes in cancer cells, according ... Medicine. , The technology uses specially designed dye-containing ... or on a single cell. , Current single-flow ...
... RequirementsTAMPA, Fla., April 15 Sage Software Healthcare, ... today announced that The Certification Commission for Healthcare ... Intergy EHR, as a CCHIT Certified(R) ... certified for Child Health and Cardiovascular Medicine, and ...
... Emory University, developed a test in nonhuman primates that ... cognitive impairment (MCI) in humans. The researchers hope the ... of Alzheimer,s disease. The test, which is featured in ... of Alzheimer,s Disease and Other Dementias , is helping ...
... Dinotefuran and Pyriproxyfen Combination Delivers Safe and Effective Control ... April 15 Summit VetPharm announces the introduction of ... flea control product containing dinotefuran and pyriproxyfen in combination ... that protects your dog from all stages of fleas ...
... Voice-Assisted Care and Pathway Health Services Bring Better ... Facilities in Long-Term CarePITTSBURGH, April 15 Vocollect ... a nationally recognized consulting and management company for ... home care markets, announce an agreement whereby Pathway ...
... April 15 ... landmark in the employee phase of the "Our House is ... and Kemmons Wilson Family Center for Good Grief as they ... began in November of 2008, with 60 employee volunteers across ...
Cached Medicine News:Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Yerkes researchers use eye tracking to detect mild dementia in humans 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 3Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 4Health News:Pathway Health Services and Vocollect Healthcare Systems Announce Strategic Partnership 2Health News:Baptist Colleagues Raise $1 Million for Baptist Trinity Hospice House and Kemmons Wilson Family Center for Good Grief 2
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... findings from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib ... antibody (a checkpoint inhibitor), suppression of tumor growth ... achieved when treating certain hematologic cancers and solid ...
(Date:2/27/2015)... Feb. 27, 2015 Securities lawyers at ... Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in ... Concerned SLXP investors are encouraged to contact attorney Hamilton ... The investigation focuses upon the shareholder value of the ... would receive only $158.00 per share in cash. At ...
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... When treating children for acute osteomyelitis--a bacterial ... to oral antibiotics is just as effective as continuing ... the oral drugs are more convenient for children and ... increased risk of complications from using central catheters, such ...
... Recombinant Factor IX (rFIX) Product for the Treatment of ... Inc., today announced the initiation of a Phase 1 ... IX (rFIX) product for control and prevention of hemorrhagic ... estimated that the market for therapies to treat this ...
Cached Medicine Technology:Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: